Zobrazeno 1 - 10
of 133
pro vyhledávání: '"Hans J, Hansen"'
Publikováno v:
PLoS ONE, Vol 7, Iss 9, p e46120 (2012)
Multiple sclerosis (MS) is associated with Epstein-Barr virus (EBV) infection, but impaired immune suppression may be part of the disease pathogenesis. CD8(+) T cells that are restricted by HLA-E exert an important immunoregulatory mechanism. To expl
Externí odkaz:
https://doaj.org/article/729f08fb4cdc45df93a3a3a2159a292c
Autor:
Douglas T. Golenbock, Marc Lamphier, Bernardo S. Franklin, Ricardo T. Gazzinelli, Marco Antonio Ataide, Jeffrey Rose, Sally T. Ishizaka, Hans J. Hansen, Fabian Gusovsky, Rosane B. de Oliveira, Wanjun Zheng
Publikováno v:
Proceedings of the National Academy of Sciences. 108:3689-3694
Excessive release of proinflammatory cytokines by innate immune cells is an important component of the pathogenic basis of malaria. Proinflammatory cytokines are a direct output of Toll-like receptor (TLR) activation during microbial infection. Thus,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0dbe08355dc26489e2ec299f87ae709
https://doi.org/10.1073/pnas.1015406108
https://doi.org/10.1073/pnas.1015406108
Autor:
Hans J. Hansen, Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg, Thomas M. Cardillo
Publikováno v:
Clinical Cancer Research. 15:6052-6061
Purpose: To improve the efficacy and reduce the gastrointestinal toxicity of the cancer prodrug, CPT-11, we have developed immunoconjugates of its active form, SN-38, and an anti-CEACAM5 antibody for targeted chemotherapy. Experimental Design: SN-38
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f98bf8cfd526a9482d7d55507615392f
https://doi.org/10.1158/1078-0432.ccr-09-0586
https://doi.org/10.1158/1078-0432.ccr-09-0586
Autor:
Christopher A. D’Souza, Thomas M. Cardillo, Serengulam V. Govindan, Hans J. Hansen, David M. Goldenberg, Sung-Ju Moon
Publikováno v:
Journal of Medicinal Chemistry. 51:6916-6926
CPT-11 is a clinically used cancer drug, and it is a prodrug of the potent topoisomerase I inhibitor, SN-38 (7-ethyl-10-hydroxycamptothecin). To bypass the need for the in vivo conversion of CPT-11 and increase the therapeutic index, bifunctional der
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96d9bab0b352a9230d1352b366d6c804
https://doi.org/10.1021/jm800719t
https://doi.org/10.1021/jm800719t
Autor:
Josette Carnahan, Hans J. Hansen, Alessandra Cesano, Zhengxing Qu, Kristen Hess, Rhona Stein, David M. Goldenberg
Publikováno v:
Molecular Immunology. 44:1331-1341
Epratuzumab is a humanized anti-CD22 monoclonal antibody currently in clinical trials for treatment of non-Hodgkin lymphoma (NHL) and certain autoimmune diseases. Here we report the results of investigations of epratuzumab's mode of action in compari
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::333c68e15b522e36551bc3746072ba7b
https://doi.org/10.1016/j.molimm.2006.05.007
https://doi.org/10.1016/j.molimm.2006.05.007
Autor:
Chien-Hsing Chang, Sailaja S. Vanama, Puja Sapra, David M. Goldenberg, Ivan Horak, Hans J. Hansen
Publikováno v:
Blood. 106:4308-4314
Ranpirnase (Rap) is a cytotoxic ribonuclease (RNase) isolated from frog oocytes. Here we describe high antitumor activity of a novel immunotoxin, 2L-Rap-hLL1-gamma4P, composed of 2 Rap molecules, each fused to the N terminus of the light chain of hLL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9568d3b957395ee6b4f7d553887fb701
https://doi.org/10.1182/blood-2005-03-1033
https://doi.org/10.1182/blood-2005-03-1033
Publikováno v:
Science in China Series D: Earth Sciences. 48:291-297
The West Pingdingshan Section in Chaohu, Southeast China’s Anhui Province is one of the potential GSSP candidates for the Induan-Olenekian boundary. Extensive study has been done on the Induan-Olenekian boundary strata at the section to meet the re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c86c3b5126989c6f44be9c5227d4f85e
https://doi.org/10.1360/04yd0361
https://doi.org/10.1360/04yd0361
Autor:
Adriane V. Rosario, Ivan Horak, Thomas M. Cardillo, Rhona Stein, Susan Chen, Zhengxing Qu, David M. Goldenberg, Hans J. Hansen
Publikováno v:
Blood. 104:3705-3711
The humanized anti-CD74 monoclonal antibody (mAb) hLL1 is under evaluation as a therapeutic agent. The effects of hLL1—at times in comparison with the CD20 mAb rituximab—were assessed on non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) cell l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf9ed6873b72bf4de51806d81dfa92f5
https://doi.org/10.1182/blood-2004-03-0890
https://doi.org/10.1182/blood-2004-03-0890
Autor:
Stephen J. Schuster, Alessandra Cesano, Amy Chadburn, John P. Leonard, Heather Ziccardi, William A. Wegener, Scott Z. Fields, David M. Goldenberg, Urte Gayko, Morton Coleman, Michael W. Schuster, Michelle Ashe, Hans J. Hansen, Richard R. Furman, Jamie C. Ketas, Michael Eschenberg, Eric J. Feldman
Publikováno v:
Clinical Cancer Research. 10:5327-5334
Purpose: We conducted a single-center, dose-escalation study evaluating the safety, pharmacokinetics, and efficacy of epratuzumab, an anti-CD22 humanized monoclonal antibody, in patients with aggressive non-Hodgkin’s lymphoma.Experimental Design: E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c1da048c873419297fe8219f2bd9aeb
https://doi.org/10.1158/1078-0432.ccr-04-0294
https://doi.org/10.1158/1078-0432.ccr-04-0294
Autor:
Zhengxing Qu, Hong Ma, Hans J. Hansen, Serengulam V. Govindan, David M. Goldenberg, Rhona Stein, Susan Chen, Gary L. Griffiths, Philip M. Andrews, Ivan Horak
Publikováno v:
Breast Cancer Research and Treatment. 84:173-182
A humanized monoclonal antibody (MAb), hRS7, labeled with 131I-IMP-R4, was evaluated for the preclinical radioimmunotherapy (RAIT) of breast cancer. 131I-IMP-R4 is an improved residualizing form of 131I that overcomes the short tumor residence time a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8dcc01d473bdb2f1277f81416a6a57da
https://doi.org/10.1023/b:brea.0000018417.02580.ef
https://doi.org/10.1023/b:brea.0000018417.02580.ef